LHP588: P. gingivalis Targeting for Alzheimer's Disease
Overview
Mermaid diagram (expand to render)
LHP588 is an investigational therapeutic developed by Lighthouse Pharmaceuticals targeting Porphyromonas gingivalis-positive patients with Alzheimer's disease (AD). This Phase 2 clinical trial (NCT06847321) represents a novel microbiome-infection approach to neurodegenerative disease treatment, focusing on the potential role of chronic periodontal infection in Alzheimer's pathogenesis["@dominy2019"][@singhrao2020]. The trial specifically enrolls patients who test positive for P. gingivalis infection, making it one of the first AD clinical trials to use a biomarker-based patient selection strategy based on infection status.
The development of LHP588 represents the continuation of a research program originally initiated by Cortexyme, Inc., which developed the gingipain inhibitor COR388 (later renamed atuzaginstat). Following Cortexyme's discontinuation of the program in 2022 due to liver toxicity concerns, Lighthouse Pharmaceuticals acquired the assets and continued development with an improved compound["@burnett2021"]. This represents a significant case study in pharmaceutical development and the challenges of bringing novel mechanisms to market for neurodegenerative diseases.
Porphyromonas gingivalis and Alzheimer's Disease
The Infection Hypothesis in Neurodegeneration
The hypothesis that microbial infections may contribute to Alzheimer's disease has gained substantial scientific attention over the past decade. This paradigm represents a significant shift from the traditional amyloid-centric view of AD pathogenesis, offering new avenues for understanding disease mechanisms and developing therapeutic interventions.
Porphyromonas gingivalis, a Gram-negative anaerobic bacterium best known for its role in chronic periodontitis (gum disease), has emerged as a leading candidate in this infection-based model of neurodegeneration[@dominy2019]. The bacterium is one of the primary pathogens associated with periodontal disease, a chronic inflammatory condition affecting the supporting structures of teeth. Importantly, the mouth maintains extensive vascular connections to the brain through the trigeminal nerve and carotid arteries, providing potential pathways for pathogen spread.
P. gingivalis is one of the most studied periodontal pathogens and is associated with:
- Chronic periodontitis affecting approximately 50% of adults over 30 years old
- Systemic inflammatory responses that can affect distant organs
- Potential invasion of the brain through multiple pathways
- Increased risk of cardiovascular disease, rheumatoid arthritis, and now potentially neurodegenerative conditions
Mechanisms of Pathogenesis
Gingipain Proteases
P. gingivalis produces a family of cysteine proteases collectively known as gingipains, which are critical virulence factors and represent the primary therapeutic target for LHP588[@dominy2019][@ilievski2018]. These enzymes are secreted in multiple forms, both as cell-associated and extracellular proteins, allowing them to exert effects far from the site of bacterial colonization.
The three main types of gingipains are:
- RgpA and RgpB (Arginine-specific gingipains): These enzymes cleave proteins at arginine residues, making them capable of processing a wide variety of host proteins. RgpA exists as a complex with hemoglobin-binding protein (HBP35), while RgpB is the free-form enzyme.
- Kgp (Lysine-specific gingivalipase): This enzyme specifically targets lysine residues and has been shown to degrade tau protein, a key pathological marker in Alzheimer's disease[@ilievski2018].
These enzymes can:
Degrade host proteins necessary for neuronal function
Activate pro-inflammatory cytokine cascades
Disrupt blood-brain barrier integrity
Directly damage neurons and glial cells
Process amyloid precursor protein in ways that may favor amyloid-β productionLipopolysaccharide (LPS)
The lipopolysaccharide (LPS) component of P. gingivalis cell walls is a potent endotoxin that can initiate powerful inflammatory responses throughout the body[@singhrao2020]. Unlike the classic understanding of LPS as solely a surface molecule, P. gingivalis LPS is also incorporated into outer membrane vesicles that bud from the bacterial surface, allowing for systemic distribution.
LPS can affect the brain through several mechanisms:
- Systemic inflammation: Circulating LPS triggers TLR4 activation on immune cells, releasing pro-inflammatory cytokines that can cross the blood-brain barrier
- Direct barrier disruption: LPS can compromise the integrity of the blood-brain barrier, allowing other bacterial products access to brain tissue
- Microglia activation: Once in the brain, LPS directly activates microglia, the brain's resident immune cells, leading to chronic neuroinflammation characteristic of AD
Direct Bacterial Invasion
Perhaps the most compelling evidence for P. gingivalis involvement in AD comes from studies demonstrating the bacterium's presence in brain tissue[@dominy2019][@singhrao2020]. Multiple independent research groups have reported:
- Detection of P. gingivalis DNA in 70-90% of AD brains versus 0% of age-matched controls
- Identification of bacterial antigens within amyloid plaques, suggesting the bacteria may become "trapped" in developing plaques
- Live bacteria observed in brain tissue from AD patients using fluorescent in situ hybridization
- Higher bacterial loads correlating with more severe pathology in some studies
The mechanisms by which P. gingivalis reaches the brain remain an active area of investigation but may include:
- Hematogenous spread through compromised blood vessels
- Retrograde transport along the trigeminal nerve, which connects the oral cavity to the brainstem
- Invasion of immune cells (Trojan horse mechanism) that traffic to the brain
Epidemiological Evidence
Multiple epidemiological studies have demonstrated associations between periodontal disease and cognitive decline[@ide2016][@chen2017], providing population-level evidence supporting the infection hypothesis:
- A 2017 Taiwanese cohort study found a significantly increased risk of AD in patients with chronic periodontitis (adjusted hazard ratio: 1.70), even after controlling for comorbidities[@chen2017]
- Longitudinal studies show that periodontal disease predicts faster cognitive decline in AD patients over 6-12 month follow-up periods[@ide2016]
- Poor oral health correlates with higher levels of AD biomarkers including amyloid-β and tau in cerebrospinal fluid
- Individuals with active periodontal disease show elevated levels of inflammatory markers associated with AD risk
Mechanism of Action
Gingipain Inhibition
LHP588 is a small molecule inhibitor designed to selectively target and inhibit gingipain protease activity[@burnett2021]. The development of this compound builds on the medicinal chemistry optimization performed during the COR388 program, with improvements aimed at enhancing safety while maintaining or improving efficacy.
The mechanism involves several interconnected steps:
Direct binding: The inhibitor molecule binds to the active site of gingipain enzymes with high affinity, blocking their proteolytic activity. The binding is reversible but long-lasting, providing sustained inhibition with appropriate dosing.
Reduction of bacterial virulence: Without functional gingipains, P. gingivalis exhibits reduced ability to invade host tissues, form biofilms, and evade immune clearance. This may help reduce the bacterial burden in infected individuals.
Protection of host proteins: Inhibition prevents degradation of neuronal proteins including tau, which is particularly vulnerable to gingipain-mediated cleavage[@ilievski2018]. This protection may help preserve neuronal structure and function.
Modulation of inflammation: By reducing bacterial load and preventing gingipain-mediated activation of inflammatory pathways, LHP588 may help normalize the chronic neuroinflammation observed in AD patients.Expected Therapeutic Effects
Based on preclinical and clinical data from COR388, gingipain inhibition may provide the following benefits:
| Potential Effect | Evidence Level | Mechanism |
|-----------------|---------------|-----------|
| Reduced neuroinflammation | Clinical (COR388) | Decreased gingipain-induced cytokine activation |
| Slowed cognitive decline | Clinical (subgroup) | Protection of neuronal function |
| Decreased tau pathology | Preclinical | Prevention of gingipain-mediated tau degradation |
| Reduced amyloid burden | Preclinical | Indirect effects on APP processing |
| Improved synaptic function | Preclinical | Protection of synaptic proteins |
The COR388 GAIN trial, though not meeting its primary endpoints in the overall population, showed a promising signal in the prespecified subgroup of participants with detectable P. gingivalis at baseline. In this population, the 80mg twice-daily dose showed a 57% slowing of cognitive decline as measured by ADAS-Cog11[@burnett2021].
Clinical Trial Design: NCT06847321
Trial Overview
| Parameter | Details |
|-----------|---------|
| Trial ID | NCT06847321 |
| Phase | Phase 2 |
| Sponsor | Lighthouse Pharmaceuticals |
| Intervention | LHP588 (oral administration) |
| Target Population | P. gingivalis-positive Alzheimer's disease patients |
| Study Design | Randomized, double-blind, placebo-controlled |
| Estimated Enrollment | ~200-300 patients |
| Status | Active, recruiting |
| Primary Endpoints | Safety, tolerability, cognitive measures |
| Secondary Endpoints | Biomarker changes, clinical outcomes |
Patient Selection Criteria
The trial uses a unique enrichment strategy by selecting only patients who test positive for P. gingivalis infection. This approach represents a significant advancement in AD clinical trial design and is based on several key observations:
Biomarker-driven enrollment: Use of oral swab, saliva testing, or other diagnostic methods to confirm P. gingivalis presence at baseline. This ensures enrolled patients have the biological target the drug is designed to inhibit.
Hypothesis-driven population: Enriching for patients most likely to benefit from the mechanism based on preclinical and clinical data showing that P. gingivalis-positive patients may respond differently to treatment[@burnett2021].
Precision medicine approach: Aligning therapeutic mechanism with patient pathophysiology represents the future of AD treatment development and may increase the probability of detecting efficacy signals.Inclusion Criteria (Typical for Phase 2 AD Trials)
- Clinical diagnosis of probable Alzheimer's disease
- MMSE score typically between 16-26 (mild to moderate AD)
- Confirmed P. gingivalis infection status
- Stable on background AD medications (if applicable)
- Able to undergo repeated cognitive testing
Exclusion Criteria (Typical)
- Significant liver disease or elevated liver enzymes
- Uncontrolled medical conditions
- Recent participation in other clinical trials
- Contraindications to the study drug
Trial Phases and Duration
- Screening period: 4-8 weeks for P. gingivalis testing and eligibility confirmation
- Treatment period: 48 weeks (similar to COR388 GAIN trial for comparison purposes)
- Follow-up: Additional 24 weeks for safety monitoring
The trial likely employs multiple dose cohorts to optimize the benefit-risk profile, learning from the liver toxicity issues observed with COR388 at higher doses[@burnett2021].
Comparison with Atuzaginstat (COR388)
Background on COR388
COR388 (later named atuzaginstat) was the first gingipain inhibitor to reach late-stage clinical development for AD[@burnett2021]. The drug's development trajectory provides important context for understanding LHP588's potential:
Phase 1 Studies (completed 2019):
- Demonstrated safety and tolerability in healthy volunteers
- Showed brain penetration using PET imaging
- Established maximum tolerated dose in AD patients
Phase 2/3 GAIN Trial:
- Enrollment: 643 participants with mild to moderate AD
- Design: Randomized, double-blind, placebo-controlled
- Doses: 40mg and 80mg twice daily
- Duration: 48 weeks
- Results: Missed co-primary endpoints (ADAS-Cog11 and ADCS-ADL) in October 2021
Discontinuation (2022):
- FDA partial clinical hold in February 2021 due to liver abnormalities
- Full clinical hold in January 2022 due to liver toxicity concerns
- Program discontinued in August 2022
- Assets acquired by Lighthouse Pharmaceuticals in January 2023
Key Differences: LHP588 vs. COR388
| Feature | LHP588 | Atuzaginstat (COR388) |
|---------|--------|----------------------|
| Company | Lighthouse Pharmaceuticals | Cortexyme/Quince Therapeutics |
| Phase | Phase 2 | Phase 2/3 (discontinued) |
| Patient selection | P. gingivalis-positive only | All mild-to-moderate AD |
| Dose | To be determined | 40mg, 80mg BID |
| Safety focus | Improved liver safety profile | Liver toxicity observed |
| Rationale | Enriched population may show greater benefit | Broad population |
| Enrollment | Targeted | GAIN trial: 643 patients |
Lessons from COR388
The GAIN trial provided invaluable insights that directly inform LHP588 development[@burnett2021]:
Subgroup efficacy signal: Perhaps the most important finding was that participants with detectable P. gingivalis at baseline showed a 57% slowing of cognitive decline on the high dose (80mg) compared to placebo. This signal, though from a subgroup analysis, strongly supports the P. gingivalis targeting approach.
Safety signal: Liver enzyme elevations (ALT/AST >3x upper limit of normal) occurred in 7% of participants on the low dose and 15% on the high dose, leading to the program's discontinuation[@burnett2021].
Dose selection: The 80mg dose showed better efficacy but also more safety issues, creating a challenging risk-benefit ratio. LHP588 may achieve similar or better efficacy at lower doses.
Endpoint sensitivity: ADAS-Cog11 may not be sensitive enough to detect treatment effects in the overall population, particularly over 48 weeks. The LHP588 trial may employ more sensitive cognitive measures or biomarker endpoints.Competitive Landscape
Other P. gingivalis-Targeting Approaches
The gingipain inhibition approach represents a unique niche in the AD therapeutic landscape, but several other programs have explored or continue to explore targeting P. gingivalis and related pathogens:
| Compound | Company | Mechanism | Status |
|----------|---------|-----------|--------|
| LHP588 | Lighthouse | Gingipain inhibitor | Phase 2 |
| Atuzaginstat | Quince Therapeutics | Gingipain inhibitor | Discontinued |
| COR395 | Quince Therapeutics | Gingipain inhibitor | Preclinical |
| Anti-P. gingivalis antibodies | Various | Passive immunization | Preclinical |
| Oral probiotics | Various | Microbial competition | Research |
Broader AD Therapeutic Landscape
The AD therapeutic market has evolved significantly in recent years, with two amyloid-targeting antibodies receiving FDA approval. LHP588 represents a fundamentally different approach:
| Approach | Target | Examples | Status |
|----------|--------|----------|--------|
| Anti-amyloid antibodies | Amyloid-β | Lecanemab, Donanemab | Approved |
| Anti-tau approaches | Tau protein | Various | Phase 2/3 |
| Neuroprotective agents | Multiple | Various | Various |
| Metabolic approaches | Brain metabolism | None yet approved | Various |
| Microbiome-based | Infection hypothesis | LHP588 | Phase 2 |
The microbiome-based approach is particularly notable because it:
- Addresses a potentially modifiable risk factor (periodontal disease)
- Targets a upstream mechanism rather than downstream pathology
- May be combinable with other therapeutic approaches
Safety Considerations
Known Risks from COR388
The discontinued COR388 program identified key safety considerations for gingipain inhibitors[@burnett2021]:
Hepatotoxicity:
- Dose-dependent liver enzyme elevations
- ALT/AST elevations >3x ULN in 7-15% of participants
- Led to trial discontinuation despite efficacy signals
Gastrointestinal Effects:
- Nausea and diarrhea in 12-15% of treated participants
- Generally mild to moderate in severity
Other Adverse Events:
- Five deaths occurred in the high-dose arm during the GAIN trial
- All deaths deemed unrelated to study drug by investigators
- No significant cognitive worsening observed
LHP588 Development Strategy
LHP588 addresses these concerns through several strategies:
Enriched patient population: Smaller trial with P. gingivalis-positive patients only may allow for more targeted dosing and better risk-benefit assessment.
Dose optimization: Lower doses may achieve similar efficacy with improved safety. The COR388 subgroup analysis suggests that P. gingivalis-positive patients may respond at lower doses.
Intensive monitoring: Enhanced liver function testing protocols, more frequent assessments, and lower thresholds for intervention.
Improved compound: Potential structural modifications for better safety profile while maintaining target engagement. The specific improvements in LHP588 over COR388 have not been publicly disclosed.Future Directions
Potential Indications
Beyond Alzheimer's disease, gingipain inhibitors may have applications in other neurodegenerative and inflammatory conditions:
- Parkinson's disease: P. gingivalis links to Lewy body pathology and α-synuclein aggregation have been reported. The COR395 program was exploring this indication.
- Vascular dementia: Infection-related cognitive impairment may be particularly relevant in vascular dementia.
- Other neurodegenerative conditions: ALS, frontotemporal dementia, and others have been linked to various microbial pathogens.
- Systemic inflammatory conditions: The anti-inflammatory effects of gingipain inhibition may have applications beyond the CNS.
Biomarker Development
Successful development of LHP588 would validate several important concepts:
- P. gingivalis testing as a diagnostic or prognostic biomarker for AD subset identification
- Gingipain activity as a treatment response markermeasurable in CSF or blood
- The infection hypothesis more broadly, potentially opening new therapeutic avenues
Combination Therapy Potential
The mechanism of LHP588 may be complementary to other AD therapeutics:
- Combined with anti-amyloid antibodies to address multiple pathological pathways
- Combined with anti-tau approaches
- Potential for synergistic effects by targeting different disease mechanisms
Cross-References
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- Porphyromonas gingivalis
- Gingipain Inhibitors
- Atuzaginstat (COR388)
- Microbiome and Neurodegeneration
- [Neuroinflammation](/mechanisms/neuroinflammation) Tau Pathology
- Amyloid Hypothesis
- Cortexyme
- Lighthouse Pharmaceuticals
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/genes/ar)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
[Dominy SS, Lynch C, Ermini F, et al, Porphyromonas gingivalis in Alzheimer's disease brains: Evidence for disease causation and treatment with small-molecule inhibitors (2019)](https://doi.org/10.1126/sciadv.aau3333)
[Singhrao SK, Harding A, Poole S, et al, Porphyromonas gingivalis Outer Membrane Vesicles Enter the Central Nervous System and Cause Neuroinflammation (2020)](https://doi.org/10.3233/JAD-200584)
[Ilievski V, Zuchowska PK, Green SJ, et al, Chronic Porphyromonas gingivalis infection accelerates the onset and progression of Alzheimer's disease pathology in 5XFAD mice (2018)](https://doi.org/10.3233/JAD-1808009)
[Ide M, Harris M, Grabsch HI, et al, Periodontitis and cognitive decline in Alzheimer's disease (2016)](https://doi.org/10.1371/journal.pone.0151081)
[Burnett D, McCollum M, Vitek R, et al, COR388 gingipain inhibitor in Alzheimer's disease: Phase 2 trial design and rationale (2021)](https://doi.org/10.1002/trc2.12267)
[Chen CK, Wu YT, Chang YC, Association between chronic periodontitis and the risk of Alzheimer's disease: A retrospective, population-based, matched-cohort study (2017)](https://doi.org/10.1016/j.jalz.2017.06.2621)
[Kantarci A, Kunkel J, Tarnow P, et al, Gingipain-dependent degradation of host proteins by Porphyromonas gingivalis (2011)](https://doi.org/10.1111/j.1600-0765.2011.01417.x)
[Poole S, Singhrao SK, Chukkapalli S, et al, Active invasion of Porphyromonas gingivalis into brain neurons and induction of Alzheimer's disease markers in mice (2015)](https://doi.org/10.3233/JAD-150247)